ImmCelz® Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients

About this update from Creative Medical Technology Holdings, Inc.

[{"type":"text","content":"Publication Supports Potent Immune Modulating Effects of JadiCell Umbilical Cord Stem Cell\n\n\nPHOENIX, Jan. 6, 2021 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTC: CELZ) commented today on a peer-reviewed publication from the University of Miami demonstrating that the intravenous administration of umbilical cord derived stem cells, termed \"JadiCells\" results in a significant survival improvement in COVID-19 patients. \n\n \n \n \n \n \n \n\n \nhttps://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.20-0472\nThe Phase 1/2 double blind, placebo-controlled trial treated 12 advanced COVID-19 patients with 100 million JadiCells™ intravenously at days 0 and 3, and 12 additional patients received placebo control. At 28 days 91% of JadiCell™ treated patients survived whereas only 42% of patients in the placebo group survived. There were no adverse effects associated with JadiCell™ administration.\n\"The ImmCelz® regenerative immunotherapy product is a personalized cellular therapy generated by co-culture of patient's immune cells with stem cells. Due to the superior nature of the JadiCell™ to other cell types, under license, we exclusively use this cell type for production of ImmCelz®,\" said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. \"The data reported today strongly supports the safety and potency of the JadiCell™, which also supports the validity of ImmCelz® which is 'powered by JadiCell™.' It should be noted that neither Creative Medical Technology Holdings nor ImmCelz® were involved in the University of Miami trial, and that Creative Medical Technology Holdings is not pursuing COVID-19 treatments at this time,\" Mr. Warbington said further.\nThe ImmCelz® cell therapy product has demonstrated efficacy in animal models of stroke, heart failure, autoimmunity, and liver failure. While the majority of companies utilize stem cell administration for therapeutic intent, ImmCelz® uses stem cells to \"reprogram\" patient immune cells, a process which endows the immune cells with ability to regenerate injured organs. \n\"It has been my pleasure to work with Timothy Warbington and his scientific team in creating a new class of cellular therapies that combines regenerative medicine with immunotherapy,\" said Amit Patel, MD, MS, inventor of the JadiCell™ and co-inventor of...

More updates from Creative Medical Technology Holdings, Inc.